GeneSight testing can identify how your body processes certain antidepressants, but its ability to predict which medication will actually work for you is limited. Studies show that people whose prescriptions were guided by GeneSight were 31% more likely to respond to their antidepressant and 57% more likely to reach remission compared to people treated without genetic guidance. Those numbers sound promising, but they come with important caveats about what the test can and cannot tell you.
What GeneSight Actually Tests
GeneSight analyzes 15 genes that fall into two categories. The first group, called pharmacokinetic genes, determines how quickly your liver breaks down medications. These include CYP2D6, CYP2C19, CYP1A2, CYP2C9, CYP3A4, CYP2B6, and several others. If you carry certain variants in these genes, you might metabolize a drug too fast (meaning it clears your system before it can work) or too slowly (meaning it builds up and causes more side effects).
The second group involves genes that affect how your brain responds to medications, including genes related to serotonin transport and certain receptors. The test also looks at a gene involved in processing the brain chemical dopamine. In total, the report covers dozens of antidepressants, antipsychotics, and other psychiatric medications.
Your results come back in a color-coded report. Green means no detected gene variations that would cause problems with that drug. Yellow flags a moderate interaction where your doctor might need to adjust the dose or monitor you more closely. Red signals a significant interaction, meaning your doctor should carefully weigh whether that medication is appropriate or whether a dose change is needed.
Where the Evidence Is Strongest
The most reliable part of GeneSight testing involves the liver metabolism genes. Clinical guidelines from the Clinical Pharmacogenetics Implementation Consortium (CPIC) already include specific, evidence-based dosing recommendations for several common antidepressants based on these genes. For example, if you’re a poor metabolizer of CYP2C19, guidelines recommend a 50% dose reduction for citalopram and escitalopram, or choosing a different medication entirely. The FDA itself caps citalopram at 20 mg per day for CYP2C19 poor metabolizers because of heart rhythm risks.
Similar guidance exists for paroxetine and CYP2D6. If you’re an ultrarapid metabolizer, meaning your body clears the drug unusually fast, guidelines recommend choosing a different antidepressant. If you’re a poor metabolizer, a 50% dose reduction is suggested. These are well-established relationships where the genetic information directly translates to practical prescribing decisions.
Not every medication on the panel has equally strong evidence, though. For fluoxetine (Prozac), for instance, the data on how CYP2D6 status affects treatment is conflicting enough that CPIC offers no firm dosing recommendation, only suggesting closer monitoring for certain metabolizer types.
Where the Evidence Falls Short
Knowing how your body breaks down a drug is not the same as knowing whether it will relieve your depression. A meta-analysis found that GeneSight-guided treatment improved remission rates by 57% and response rates by 31% compared to standard care. But the American Psychiatric Association reviewed the full body of evidence in both 2018 and 2024, and both times concluded there is still not enough evidence to support widespread use of pharmacogenetic tests for depression treatment.
One core problem is that depression is influenced by far more than genetics. Age has a significant effect on outcomes, with younger patients consistently doing better across studies. Ethnicity, medication history, psychosocial circumstances, and even the placebo effect all shape how someone responds to an antidepressant. None of these factors show up on a genetic test.
There’s also a phenomenon called phenoconversion, where other medications, supplements, or foods temporarily change how your liver enzymes work, effectively making your actual metabolism different from what your genes predict. If you’re taking a drug that inhibits one of your liver enzymes, your GeneSight results might say you’re a normal metabolizer when you’re functionally acting like a poor one. Studies have noted that phenoconversion is rarely measured or accounted for in the research supporting these tests.
The FDA’s Position
The FDA has taken a cautious stance on pharmacogenetic testing for antidepressants. The agency has issued warnings about tests that claim to predict how patients will respond to specific medications when those claims haven’t been established in drug labeling. In a warning letter to one genomics lab, the FDA stated it was “particularly concerned about pharmacogenetic tests that claim to predict patients’ responses to specific medications where such claims have not been established.”
The agency’s concern is practical: if patients or doctors change doses or switch medications based on test results that haven’t been validated, it could lead to incorrect treatment or worsening illness. The FDA does recognize pharmacogenetic information when it’s backed by strong enough evidence to be included in a drug’s official labeling, as with the citalopram dosing cap for CYP2C19 poor metabolizers. But many of the gene-drug relationships covered by GeneSight haven’t reached that threshold.
What the Test Is Best At
GeneSight is most useful for identifying potential problems rather than picking winners. It’s better at flagging medications you’re likely to have trouble with, either because you’ll metabolize them too quickly for them to work or too slowly for them to be safe, than at predicting which drug will lift your depression. Think of it less as a crystal ball and more as a screening tool that can help narrow the options.
The test tends to be most valuable for people who have already tried multiple antidepressants without success. If you’ve failed several medications, knowing whether a metabolic mismatch contributed to those failures can help your doctor make a more informed next choice. For someone starting their first antidepressant, the added value is less clear, since most people respond reasonably well to first-line treatments chosen based on symptoms and side effect profiles alone.
Cost and Coverage
Medicare Part B covers GeneSight with no out-of-pocket cost when the test is medically necessary, which generally requires a diagnosis of moderate or severe major depressive disorder. Medicaid typically covers it at no cost as well. With commercial insurance, your share varies by plan but is capped at $330 under the company’s pricing promise. Financial assistance programs are available based on household income, and interest-free payment plans exist for costs of $100 or more.
Medicare and insurers generally require documentation that the test results will directly inform a prescribing decision, meaning your doctor needs to record which medications are being considered and why genetic information would change the approach. Only one test per date of service is covered, so you can’t run multiple panels simultaneously.
Putting It in Perspective
GeneSight testing provides real, actionable genetic information about drug metabolism that can help avoid certain prescribing pitfalls. The metabolism data for specific drugs like citalopram, escitalopram, and paroxetine is well supported and already built into clinical guidelines. But the broader promise, that a cheek swab can tell you which antidepressant will work best, outpaces the current evidence. Your genes are one piece of a much larger puzzle that includes your medical history, other medications, lifestyle factors, and the nature of your depression itself. The test is a useful tool when interpreted carefully by a knowledgeable prescriber, not a definitive answer on its own.